Fintepla is an oral solution developed to treat seizures associated with Dravet syndrome, a rare, lifelong form of epilepsy that begins in infancy. The condition affects around one in every 15,000 people in the UK.
The condition is marked by severe refractory seizures – seizures that are not brought under control by medicine – frequent medical emergencies, significant cognitive and behavioural impairments, and a significantly increased risk of sudden unexpected death in epilepsy (SUDEP)…
